Literature DB >> 28579677

Decision Making for Selection of Transarterial Locoregional Therapy of Metastatic Neuroendocrine Tumors.

Ron C Gaba1,2, Nasya Mendoza-Elias3, Joseph D Morrison3, Ali Kord Valeshabad1, Andrew J Lipnik1,2.   

Abstract

Transarterial locoregional therapies (LRTs) are indispensable components of the modern interventional oncologic therapy of liver-dominant metastatic neuroendocrine tumors (NETs). The scope of available LRTs and their nuanced differences mandates a thorough understanding of their relative applicability and effectiveness in certain clinical circumstances to prescribe appropriate, patient-specific, image-guided therapy. This article aims to provide an overview of transarterial LRT options for liver-dominant metastatic NETs and therapy selection by reviewing procedure types, their advantages and disadvantages, and comparative efficacy in common case scenarios.

Entities:  

Keywords:  Interventional radiology; locoregional therapy; metastatic; neuroendocrine tumor

Year:  2017        PMID: 28579677      PMCID: PMC5453770          DOI: 10.1055/s-0037-1602590

Source DB:  PubMed          Journal:  Semin Intervent Radiol        ISSN: 0739-9529            Impact factor:   1.513


  40 in total

1.  Phase II study of chemoembolization with drug-eluting beads in patients with hepatic neuroendocrine metastases: high incidence of biliary injury.

Authors:  Nikhil Bhagat; Diane K Reyes; Mingde Lin; Ihab Kamel; Timothy M Pawlik; Constantine Frangakis; J F Geschwind
Journal:  Cardiovasc Intervent Radiol       Date:  2012-06-22       Impact factor: 2.740

2.  Factors predicting response and survival after yttrium-90 radioembolization of unresectable neuroendocrine tumor liver metastases: a critical appraisal of 48 cases.

Authors:  Akshat Saxena; Terence C Chua; Lourens Bester; Adel Kokandi; David L Morris
Journal:  Ann Surg       Date:  2010-05       Impact factor: 12.969

3.  Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes.

Authors:  Khairuddin Memon; Robert J Lewandowski; Mary F Mulcahy; Ahsun Riaz; Robert K Ryu; Kent T Sato; Ramona Gupta; Paul Nikolaidis; Frank H Miller; Vahid Yaghmai; Vanessa L Gates; Bassel Atassi; Steven Newman; Reed A Omary; Al B Benson; Riad Salem
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-12-02       Impact factor: 7.038

4.  Pyogenic abscess after hepatic artery embolization: a rare but potentially lethal complication.

Authors:  James J Mezhir; Yuman Fong; Deborah Fleischer; Susan K Seo; Francesco D'Amico; Elena Petre; Anne M Covey; George I Getrajdman; Raymond H Thornton; Stephen B Solomon; William R Jarnagin; Karen T Brown
Journal:  J Vasc Interv Radiol       Date:  2010-12-31       Impact factor: 3.464

5.  Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.

Authors:  Eric Raymond; Laetitia Dahan; Jean-Luc Raoul; Yung-Jue Bang; Ivan Borbath; Catherine Lombard-Bohas; Juan Valle; Peter Metrakos; Denis Smith; Aaron Vinik; Jen-Shi Chen; Dieter Hörsch; Pascal Hammel; Bertram Wiedenmann; Eric Van Cutsem; Shem Patyna; Dongrui Ray Lu; Carolyn Blanckmeister; Richard Chao; Philippe Ruszniewski
Journal:  N Engl J Med       Date:  2011-02-10       Impact factor: 91.245

Review 6.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Authors:  James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

7.  Conventional versus Drug-Eluting Bead Transarterial Chemoembolization for Neuroendocrine Tumor Liver Metastases.

Authors:  Mina S Makary; Jordan Kapke; Vedat Yildiz; Xueliang Pan; Joshua D Dowell
Journal:  J Vasc Interv Radiol       Date:  2016-08-04       Impact factor: 3.464

8.  Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience.

Authors:  Sanjay Gupta; James C Yao; Kamran Ahrar; Michael J Wallace; Frank A Morello; David C Madoff; Ravi Murthy; Marshall E Hicks; Jaffer A Ajani
Journal:  Cancer J       Date:  2003 Jul-Aug       Impact factor: 3.360

9.  Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients.

Authors:  Andrew S Kennedy; William A Dezarn; Patrick McNeillie; Doug Coldwell; Charles Nutting; Dennis Carter; Ravi Murthy; Steven Rose; Richard R P Warner; David Liu; Holger Palmedo; Carroll Overton; Bonita Jones; Riad Salem
Journal:  Am J Clin Oncol       Date:  2008-06       Impact factor: 2.339

10.  Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients.

Authors:  P Ruszniewski; P Rougier; A Roche; P Legmann; A Sibert; S Hochlaf; M Ychou; M Mignon
Journal:  Cancer       Date:  1993-04-15       Impact factor: 6.860

View more
  2 in total

1.  Costs of Cancer Care for Elderly Patients with Neuroendocrine Tumors.

Authors:  Chan Shen; Arvind Dasari; Dian Gu; Yiyi Chu; Shouhao Zhou; Ying Xu; Daniel Halperin; Shuangshuang Fu; James C Yao; Ya-Chen Tina Shih
Journal:  Pharmacoeconomics       Date:  2018-08       Impact factor: 4.981

2.  Outcomes and toxicity following Yttrium-90 radioembolization for hepatic metastases from neuroendocrine tumors-a single-institution experience.

Authors:  Darryl A Zuckerman; Richard F Kennard; Amit Roy; Parag J Parikh; Ashley A Weiner
Journal:  J Gastrointest Oncol       Date:  2019-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.